Home / Market News / $NBIX
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Analysts Adjust Price Targets for Neurocrine Biosciences

Nov 3, 2026, 2:37 PM UTC · Primary ticker $NBIX

This filing discloses that two major financial institutions, RBC Capital Markets and Deutsche Bank, have updated their price targets for Neurocrine Biosciences following the company's Q3 2026 earnings report. While both raised their targets, their ratings differ, indicating varied analyst sentiment on the stock's future performance.

On November 3, 2026, RBC Capital Markets and Deutsche Bank both increased their price targets for Neurocrine Biosciences (NBIX) after the company released its Q3 2026 earnings report on November 2, 2026. RBC raised its target to $190 from $187, maintaining an 'Outperform' rating, while Deutsche Bank increased its target to $175 from $165, keeping a 'Hold' rating. This indicates that the Q3 earnings report was generally perceived as positive enough to warrant upward revisions in valuation, though the differing ratings suggest continued divergence in long-term outlooks among analysts. For traders, this news provides a short-term positive sentiment boost for NBIX, as analyst upgrades often lead to increased investor interest. However, the 'Hold' rating from Deutsche Bank tempers the overall enthusiasm, suggesting that while the company is performing well, significant upside might be limited in their view. The key opportunity for traders lies in potential short-term price appreciation driven by the target increases, but the mixed ratings introduce a risk of limited sustained upward momentum.

$NBIX positive Analyst price target increases
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.